Ser158

Site Information
CADGKKPsSPPEELK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 451052

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 2 , 3 ) , mutation of modification site ( 1 , 2 , 3 )
Disease tissue studied:	leukemia ( 3 ) , acute myelogenous leukemia ( 3 ) , lymphoma ( 3 ) , cancer, squamous cell carcinoma ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 1 ) , A431 (epithelial) ( 2 ) , HEp-3 ( 1 ) , HL60 (myeloid) ( 3 ) , THP1 (myeloid) ( 3 ) , U-937 (myeloid) ( 3 )

Downstream Regulation
Effects of modification on uPA:	activity, inhibited ( 2 ) , intracellular localization ( 3 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:	cell adhesion, altered ( 3 ) , cell motility, altered ( 1 , 3 ) , cytoskeletal reorganization ( 1 )
Induce interaction with:	ITGA5 (human) ( 1 ) , ITGB5 (human) ( 1 )

References
1	Vocca I, et al. (2009) Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation. Int J Cancer 124, 316-25 18844213 Curated Info
2	Franco P, et al. (1998) Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J Biol Chem 273, 27734-40 9765311 Curated Info
3	Franco P, et al. (1997) Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J Cell Biol 137, 779-91 9151681 Curated Info